We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Read MoreHide Full Article
Biogen Inc. (BIIB - Free Report) exercised its option to enter into an exclusive, global license agreement with California-based private biotechnology company, Amunix Operating Inc., to incorporate the latter’s proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.
Biogen’s share price has gained 3.4% in the past one year compared with the Zacks classified Medical-Biomedical and Genetics industry’s fall of 17.3%. The agreement is part of Biogen’s hemophilia business, which will be spinnig off on Feb 1, 2017. The new business will be called Bioverativ Inc. and will become an independent, publicly-traded company.
Bioverativ will focus on the research, development and commercialization of innovative therapies to address areas of serious unmet need for people with hemophilia and other rare blood disorders.
Per terms of the agreement, Amunix will receive an upfront $1.25-million payment and will also be entitled to receive up to $17.25 million in clinical and commercial milestone payments. Amunix will also receive royalties on commercial sales from Factor IX products that incorporate its XTEN technology.
The collaboration between Biogen and Ammunix dates back to 2011, when they entered into a Research and Option Agreement, under which the companies had agreed to utilize Amunix' expertise in protein half-life extension and its XTEN technology Biogen’s expertise in both hemophilia and engineering long-lasting coagulation factors.
Zacks Rank & Key Picks
Biogen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Arena Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex sports a Zacks Rank #1 (Strong Buy), Arena and Anika carry a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 Rank stocks here.
Cambrex has posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 31.2% in the past one year.
Arena has posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 11.43%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5% respectively over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 36.9% in the past one year.
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research.See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Biogen Inc. (BIIB - Free Report) exercised its option to enter into an exclusive, global license agreement with California-based private biotechnology company, Amunix Operating Inc., to incorporate the latter’s proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate.
Biogen’s share price has gained 3.4% in the past one year compared with the Zacks classified Medical-Biomedical and Genetics industry’s fall of 17.3%.
The agreement is part of Biogen’s hemophilia business, which will be spinnig off on Feb 1, 2017. The new business will be called Bioverativ Inc. and will become an independent, publicly-traded company.
Bioverativ will focus on the research, development and commercialization of innovative therapies to address areas of serious unmet need for people with hemophilia and other rare blood disorders.
Per terms of the agreement, Amunix will receive an upfront $1.25-million payment and will also be entitled to receive up to $17.25 million in clinical and commercial milestone payments. Amunix will also receive royalties on commercial sales from Factor IX products that incorporate its XTEN technology.
The collaboration between Biogen and Ammunix dates back to 2011, when they entered into a Research and Option Agreement, under which the companies had agreed to utilize Amunix' expertise in protein half-life extension and its XTEN technology Biogen’s expertise in both hemophilia and engineering long-lasting coagulation factors.
Zacks Rank & Key Picks
Biogen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Arena Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex sports a Zacks Rank #1 (Strong Buy), Arena and Anika carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex has posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 31.2% in the past one year.
Arena has posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 11.43%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5% respectively over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 36.9% in the past one year.
BIOGEN INC Price
BIOGEN INC Price | BIOGEN INC Quote
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>